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ABSTRACT 
Nagashima-type palmoplantar keratosis (NPPK) is an autosomal recessive skin disorder 
with a high, unmet medical need that is caused by mutations in SERPINB7. Almost all 
NPPK patients carry the founder nonsense mutation c.796C>T (p.Arg266Ter) in the last 
exon of SERPINB7. Here we sought to determine whether topical 
“nonsense-suppression (readthrough)” therapy using gentamicin is applicable to NPPK. 
First, we demonstrated that gentamicin enhanced readthrough activity in cells 
transfected with SERPINB7 cDNA carrying the mutation and promoted full-length 
SERPINB7 protein synthesis in NPPK keratinocytes. We next conducted an 
investigator-blinded, randomized, bilaterally controlled compassionate use study of 
topical gentamicin in which five NPPK patients with c.796C>T were enrolled. Patients’ 
selfreported improvement of hyperkeratosis was significantly greater on the gentamicin 
side than the control side (P=0.0349). In two patients, hyperkeratosis was improved on 
the gentamicin side, as determined by a blinded-investigator assessment. These results 
indicate the therapeutic potential of topical gentamicin for NPPK. Unexpectedly, we 
also found that mutant SERPINB7 mRNAs harboring r.796c>u were degraded by 
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nonsense-mediated mRNA decay. Furthermore, the truncated SERPINB7 protein was 
degraded via a proteasome-mediated pathway. These findings provide important 
insights into the mRNA/protein quality control system in humans, which could be a 
potential therapeutic target for genetic diseases. (199 words) 
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INTRODUCTION 
Nagashima-type palmoplantar keratosis (NPPK; MIM#615598) is the most common 
form of palmoplantar keratodermas in East Asian populations and is inherited in an 
autosomal recessive fashion (Kubo et al., 2013; Kubo et al., 2014). NPPK is clinically 
characterized by diffuse and “transgressive” hyperkeratosis and erythema on the palms 
and soles extending to the dorsum of the hands and the feet, the flexor aspects of the 
wrists and the ankles, and the Achilles tendon areas, often involving the elbows and 
knees (Kabashima et al., 2009; Kubo et al., 2013). Loss-of-function mutations (mostly 
nonsense mutations) in the gene encoding SERPINB7, a member of the serine protease 
inhibitor superfamily highly expressed in the stratum granulosum, have been shown to 
cause NPPK (Kubo et al., 2013). However, there is still no curative therapy for NPPK, 
and current disease management strategies primarily aim to reduce hyperkeratosis using 
topical vitamin D3 and/or topical keratolytics, such as salicylic acid, urea, and 
adapalene, which produce unsatisfactory outcomes. 
 
Nonsense mutations account for approximately 11% and 20% of disease-causing gene 
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lesions and single-base-pair mutations, respectively, with some genes showing 
considerably higher nonsense mutation frequencies (Mort et al., 2008). Nonsense 
mutations create a premature termination codon (PTC)—UGA, UAG, or UAA—which 
usually triggers degradation of PTC-containing mRNAs by mRNA quality control 
pathways to reduce the production of a potentially deleterious truncated protein. PTC 
recognition is largely mediated by protein complexes called exon-junction complexes 
(EJCs), which are deposited 20-24 nucleotides upstream of exon-exon junctions during 
pre-mRNA splicing (Le Hir et al., 2000; Shoemaker and Green., 2012). In the pioneer 
round of translation, ribosomes displace EJCs, and a PTC is distinguished from a 
canonical stop codon by the presence of one or more EJCs downstream of a stop codon 
(Maquat et al., 2010; Shoemaker and Green., 2012). PTC-containing mRNAs are then 
subjected to nonsense-mediated mRNA decay (NMD). Importantly, the first step of this 
process is mediated by the recruitment of up-frameshift protein 1 (UPF1), which is a 
key NMD factor, by the ribosome stalled on a PTC (Kurosaki and Maquat., 2016). 
Because NMD reduces the PTC-containing mRNA level to ∼5–25% of the PTC-free 
mRNA level, ribosomes translate only mutant transcripts that escape NMD into 
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truncated protein (Kervestin and Jacobson., 2012; Kuzmiak and Maquat., 2006). 
Importantly, translational termination by a PTC is not 100% efficient, and decoding of 
the stop codon by a near-cognate tRNA occurs at a low frequency (Bidou et al., 2012). 
This natural suppression of PTCs, so-called “readthrough”, can lead to the restoration of 
a full-length protein (Bidou et al., 2012). Indeed, the therapeutic potential of 
readthrough-enhancing drugs, including aminoglycoside antibiotics (gentamicin, G418, 
paromomycin, and amikacin) and ataluren (Translarna®, formerly known as PTC124), 
has been verified in cell-based assays, cultured mammalian cells, animal models, and 
even human patients with nonsense mutations (Barton-Davis et al., 1999; Bidou et al., 
2012; Roy et al., 2016; Welch et al., 2007; Wilschanski et al., 2003). Nevertheless, the 
clinical usage of these drugs for genetic diseases remains very limited, largely because 
systemic aminoglycosides have renal and otic toxicities, and these readthrough agents 
show considerably varying readthrough efficiencies among the target nonsense 
mutations (Manuvakhova et al., 2000). Notably, the levels of readthrough for a given 
nonsense mutation mainly depend on the context of the stop codon (UGA > UAG > 
UAA) and the identity of the nucleotide immediately downstream from the stop codon 
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(for example, UGAC > UGAA > UGAU, UGAG) (Manuvakhova et al., 2000). 
Furthermore, higher mutant transcript levels ensure more synthesis of 
readthrough-generated full-length protein, i.e., the degradation of PTC-containing 
mRNAs by NMD represents a limitation of nonsense suppression strategies (Bidou et 
al., 2012; Linde et al., 2007). 
 
We hypothesized that NPPK represents an ideal readthrough target because more than 
90% of the reported patients carry the TGAA nonsense mutation c.796C>T (Hashimoto 
et al., 2017; Hida et al., 2015; Kubo et al., 2013; Li et al., 2016; Miyauchi et al., 2016; 
Mizuno et al., 2014; Nakajima et al., 2016; On et al., in press; Shiohama et al., 2015; 
Suzuki et al., 2015; Yin et al., 2014; Zhang et al., 2016), and the mutant mRNA is likely 
to escape NMD, as it occurs in the last exon of the gene. The estimated number of 
NPPK patients carrying c.796C>T is extremely large—at least 0.15 million in Japan and 
China—because the allele frequency of this mutation is higher than 0.01 in the Japanese 
and Chinese populations (Kubo et al., 2013), which again makes the mutation a very 
attractive therapeutic target. Furthermore, given that SERPINB7 is highly expressed by 
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keratinocytes in the stratum granulosum (Kubo et al., 2013), topical application of 
readthrough-promoting compounds appears to elicit full-length protein synthesis. 
Because production of a small amount of functional protein has been shown to be 
sufficient for clinical improvement in a number of autosomal recessive disorders such 
as McArdle disease (Haller and Vissing., 2002), even partial restoration of full-length 
SERPINB7 by readthrough agents should attenuate the NPPK phenotype. 
 
In this study, we investigated the potential of gentamicin and ataluren to promote 
readthrough of c.796C>T in SERPINB7 in vitro and demonstrated that gentamicin 
suppresses the nonsense mutation in a dose-dependent manner. We also performed a 
“proof-of-concept” compassionate use study of topical gentamicin for NPPK, which 
showed that a four-week application of gentamicin ameliorated its clinical phenotypes. 
These results collectively highlight the therapeutic potential of topical gentamicin for 
NPPK. Furthermore, we unexpectedly found that mutant SERPINB7 mRNAs harboring 
the mutation were degraded by NMD and that truncated SERPINB7 was digested by a 
proteasome-mediated pathway. Because little is known about the mechanisms 
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contributing to the degradation of mRNAs with a nonsense mutation in the last exon of 
a human gene and its protein products, these findings should expand our understanding 
of the mRNA/protein quality control system and facilitate a novel therapeutic approach 
for the treatment of genetic diseases. 
 
RESULTS 
Gentamicin restores full-length SERPINB7 via c.796C>T readthrough in 
SERPINB7 cDNA 
We first sought to determine whether gentamicin can promote readthrough of the 
nonsense mutation c.796C>T in SERPINB7 in vitro. Mutant SERPINB7 cDNA 
harboring c.796C>T was transfected into AD293 cells together with a firefly luciferase 
(FLuc) gene, which was used to normalize transfection efficiency (Figure 1a). In theory, 
the baseline production of full-length SERPINB7 is close to zero, whereas its 
production would increase if gentamicin allows ribosomes to ignore the PTC (Figure 
1b). The cells were subsequently treated with eight different concentrations of 
gentamicin (39-10,000 µg/ml). Gentamicin restored the production of full-length 
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SERPINB7 at concentrations between 312 and 5,000 µg/ml in a dose-dependent manner, 
while the protein signal at 10,000 µg/ml slightly decreased compared with that at 5,000 
µg/ml (Figure 1c). By contrast, gentamicin did not increase FLuc production. Thus, we 
clearly demonstrated that gentamicin can promote readthrough of c.796C>T in 
SERPINB7 cDNA. 
 
Ataluren does not promote readthrough of c.796C>T in SERPINB7 cDNA 
AD293 cells transiently transfected with the mutant SERPINB7 cDNA were similarly 
treated with a broad range of concentrations of ataluren (1.56-100 µM). Intriguingly, 
ataluren was not able to restore full-length SERPINB7 production at any concentration 
tested (Figure 1c). Rather, ataluren enhanced the FLuc signal, probably by increasing 
protein stability (Figure 1c).  
 
Gentamicin enhances full-length SERPINB7 protein production in NPPK 
keratinocytes 
Next, we investigated the readthrough efficiency of gentamicin using immortalized 
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primary keratinocytes derived from an NPPK patient homozygous for c.796C>T (P1 in 
the Table 1). The immortalized NPPK keratinocytes were treated with 10,000 or 15,000 
µg/ml of gentamicin. The cell lysates were subjected to Western blotting analysis using 
an antibody against the N-terminus of SERPINB7 to detect full-length SERPINB7. 
Because a number of non-specific bands were observed when this antibody was used to 
analyze keratinocyte lysates, we first characterized the antibody to differentiate between 
specific and non-specific bands using small interfering RNA (siRNA) knockdown of 
SERPINB7 and identified a SERPINB7-specific band (Figure 2). Using this antibody, 
we found that gentamicin treatment restored full-length SERPINB7 at both 
concentrations (Figure 2), although it reduced the cell viability of keratinocytes at these 
concentrations (data not shown). In contrast, little SERPINB7 was detected when the 
cells were untreated (Figure 2). Thus, we confirmed that gentamicin suppresses 
c.796C>T in NPPK patient-derived keratinocytes. 
 
Compassionate use study of topical gentamicin in NPPK patients with c.796C>T 
To verify the in vivo readthrough potential of gentamicin, we next conducted an 
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investigator-blinded, randomized, bilaterally controlled compassionate use study of 
topical gentamicin. In brief, five NPPK patients (Table 1)—three homozygotes for 
c.796C>T and two compound heterozygotes for c.796C>T and c.455-1G>A—were 
instructed to apply 0.1% gentamicin ointment, which is made from Vaseline, on one 
hand and Vaseline alone as a control on the other hand for four weeks, and the side that 
received each treatment was randomly assigned. Because one homozygote (P5 in the 
Table 1) reported to us on day 21 that pruritic erythema and vesicles had appeared 
exclusively on the dorsum of the gentamicin-applied hand on day 14, he was asked to 
stop using gentamicin ointment on day 21 and thereafter. Considering that he was 
patch-test negative to gentamicin and that pruritic erythema and vesicles were not 
observed on the gentamicin-applied palm, we concluded that he had developed acute 
eczema, but not contact dermatitis. Topical gentamicin was well tolerated by the 
remaining four patients, as they showed no clinical signs of systemic or local toxicity. 
Notably, the gentamicin side showed a significantly greater reduction in visual analog 
scale (VAS) scores with regard to hyperkeratosis than the control side after a four-week 
treatment (mean ± standard error of the mean (SEM); 19 ± 3.32 vs 3 ± 2; P=0.0349; 
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Figure 3a and Supplementary Table 1). By a blinded-investigator assessment, 
hyperkeratosis was improved on the gentamicin side in two homozygotes (P1 and P5 in 
the Table 1) (Figure 3b and Supplementary Figure S1). Reduced scaling and 
smoothening of their palmar skin surfaces were also noted (Figure 3b and 
Supplementary Figure S1). Although topical gentamicin did not improve the degree of 
erythema by either subjective or objective assessment in any of the patients 
(Supplementary Table S2), subjective and objective assessments illustrated that it 
suppressed hyperkeratosis in four and two patients by, respectively. 
 
Degradation of mutant SERPINB7 mRNA by NMD 
Because c.796C>T is located in the last exon of SERPINB7, we initially hypothesized 
that the mutant mRNA might not be degraded by NMD in keratinocytes carrying the 
mutation. To validate this hypothesis, we first determined the expression levels of 
SERPINB7 mRNA in the skin of eight individuals—five were homozygous and three 
were wild type for c.796C>T—using quantitative real-time reverse transcriptase PCR. 
Unexpectedly, the expression levels of SERPINB7 mRNA in the homozygotes were 
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47% lower than those in the wild-type individuals, and this difference was statistically 
significant (P=0.00069) (Figure 4a). To address the mechanism underlying the decrease, 
we next treated immortalized NPPK keratinocytes with cycloheximide (CHX), an 
inhibitor of translation, and quantified the mutant transcript levels. Notably, 
CHX-treated NPPK keratinocytes showed a greater increase in nonsense-containing 
SERPINB7 mRNA levels than CHX-treated immortalized normal human epidermal 
keratinocytes (NHEKs; Figure 4b), which clearly indicates that translation-coupled 
mRNA degradation is involved in this process. Furthermore, siRNA knockdown of 
UPF1 led to a statistically significant increase in the stability of mutant SERPINB7 
mRNA in immortalized NPPK keratinocytes compared with cells transfected with a 
scramble siRNA (P=0.00157 and 0.00022 for siRNA#1 and siRNA#2, respectively) 
(Figure 4c). In contrast, UPF1 knockdown did not increase SERPINB7 mRNA levels in 
the immortalized NHEKs (Figure 4c). These data collectively indicate that NMD occurs 
for the nonsense mutation c.796C>T, despite the mutant transcript lacking a 
downstream EJC (EJC-independent NMD).  
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Proteasome-mediated degradation of truncated SERPINB7 protein 
When we transfected the mutant and wild-type SERPINB7 cDNA into HaCaT cells, we 
found that the protein level of truncated SERPINB7 was greatly reduced compared with 
that of full-length SERPINB7 (Figures 1a and 5a). Although EJC-independent NMD 
alone may explain the lower protein expression in the mutant-transfected cells, we 
wondered whether additional proteasome-mediated protein degradation might underlie 
this process. To address this, we measured the protein levels of SERPINB7 after 
treating the mutant-transfected cells with MG132, a 26S proteasome inhibitor. Notably, 
the addition of MG132 increased protein levels, whereas MG132 treatment did not alter 
protein levels in the wild-type-transfected cells (Figure 5a). Similarly, treatment of 
immortalized NPPK keratinocytes with MG132 dose-dependently increased the 
production of truncated SERPINB7 (Figure 5b). These results collectively led us to 
conclude that the truncated SERPINB7 proteins synthesized from PTC-containing 
transcripts are regulated by the 26S proteasome-mediated protein degradation pathway. 
 
DISCUSSION 
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In this study, we clearly demonstrated that gentamicin suppresses c.796C>T in cells 
transiently transfected with the mutant SERPINB7 cDNA and in NPPK keratinocytes. 
These results suggest that c.796C>T is a “good responder” mutation to readthrough 
therapy using gentamicin. Furthermore, topical 0.1% gentamicin ameliorated 
hyperkeratosis in patients with NPPK, indicating its promise for the treatment of NPPK. 
Before this study, no randomized controlled clinical study had been performed using 
topical readthrough agents. There was only one report of a non-blinded, 
non-randomized, single-patient clinical study of topical gentamicin for Hailey-Hailey 
disease (MIM#169600), an autosomal dominant blistering disease, where gentamicin 
yielded slightly better clinical improvements of a submammary skin eruption in a 
patient harboring a heterozygous TGA nonsense mutation (c.1402C>T; p.Arg468Ter) in 
ATP2C1 compared with a topical preparation containing 5% boric acid and 2% salicylic 
acid (Kellermayer et al., 2006). In revising our manuscript, we learned that a 
double-blind, placebo-controlled pilot trial of gentamicin for recessive dystrophic 
epidermolysis bullosa (MIM#226600) was recently published (Woodley et al., 2017). In 
this study, five patients carrying nonsense mutations in COL7A1 showed a significant 
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increase in type VII collagen expression via topical or intradermal administration of the 
drug. Thus, we provide further “proof-of-concept” clinical data supporting the 
therapeutic potential of topical gentamicin in an autosomal recessive disorder. However, 
an important question—what percentage of physiological SERPINB7 protein level 
provides reasonable epidermal homeostasis—has yet to be answered. In our 
compassionate use study, improvement of erythema was not observed in any participant, 
which suggests the following two possibilities: (1) More synthesis of SERPINB7 is 
required to completely cure the disease, or (2) some of gentamicin-induced SERPINB7 
may not be fully functional because aminoglycosides induce ribosomes to readthrough 
PTCs via the incorporation of random amino acids by near-cognate aminoacyl tRNAs. 
Nevertheless, the regression of hyperkeratosis seen on the gentamicin-treated hands is 
sufficiently promising to warrant a larger confirmatory trial of topical gentamicin in 
NPPK and other genetic skin disorders caused by nonsense mutations with limited 
therapeutic options. Furthermore, a longer treatment and observation period should be 
considered in future studies. Given that gentamicin is associated with nephrotoxicity 
and ototoxicity, one could hypothesize that a long use of topical gentamicin would 
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result in these severe adverse events. However, this does not appear to be the case with 
NPPK, because the topical daily dose of 0.1% gentamicin ointment used in our study 
was much lower than that used in previously reported clinical studies, in which systemic 
gentamicin exhibited neither nephrotoxicity nor ototoxicity (Malik et al., 2010); this 
would be the case even if 100% of the topical gentamicin had entered the patients’ 
bloodstream. Rather, we speculate that allergic skin reactions may represent a limitation 
of the therapeutic application of topical gentamicin, considering its allergic potential 
(Gehrig and Warshaw., 2008). 
 
In contrast, this study demonstrated that ataluren did not enhance the production of 
full-length SERPINB7 from the mutant cDNA carrying c.796C>T at concentrations of 
1.56-100 µM, indicating that ataluren is not capable of suppressing the mutation. 
Ataluren was originally identified by high-throughput screening for small molecules 
that increased the frequency of readthrough of a UGA PTC in an FLuc gene, possibly 
by promoting the insertion of a near-cognate tRNA at the PTC site (Roy et al., 2016; 
Welch et al., 2007). Although more than 20 nonsense suppression experiments in 
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cell-based or animal models have suggested the readthrough ability of ataluren (Peltz et 
al., 2013; Roy et al., 2016), our results challenge this view. In support of our results, 
studies have cast doubt on its efficacy and its underlying mechanism of action (Auld et 
al., 2009; Auld et al., 2010; Brumm et al., 2012; McElroy et al., 2013). Ataluren could 
not rescue the two PTCs (UGAG and UAGU) in the collagen type VII gene (COL7A1) 
at concentrations of 0.01-100 µM (McElroy et al., 2013) or the four PTCs (UGAA, 
UAAU, UAGA, and UAAG) in the melanocortin 4 receptor gene (MCR4) at 
concentrations of 7.5 or 75 µg/ml (Brumm et al., 2012), whereas aminoglycosides did 
enhance readthrough of these PTCs. A phase 3 trial in cystic fibrosis also failed to hit its 
primary endpoint and reach statistical significance (Kerem et al., 2014). Furthermore, 
ataluren’s ability to suppress nonsense codons may be an artifact of the FLuc reporter 
assay that was used to discover the drug, because it stabilizes FLuc, an enzyme that is 
otherwise rapidly degraded (Auld et al., 2009; Auld et al., 2010; McElroy et al., 2013). 
Although identifying the precise molecular target of ataluren could resolve these issues, 
this study demonstrated that ataluren does not suppress c.796C>T in SERPINB7 but 
increases FLuc protein levels. 
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NMD triggered by c.796C>T in the last exon of SERPINB7 is intriguing because the 
EJC-dependent PTC recognition model predicts that mRNAs with a nonsense mutation 
in a terminal exon of a given gene are stable, as they lack a downstream EJC, which 
defines the stop codon as premature (Kurosaki and Maquat., 2016). In human diseases, 
EJC-independent NMD has been experimentally verified only in patients with Schmid 
metaphyseal chondrodysplasia (MIM#156500) carrying three specific PTC 
mutations—p.Tyr632Ter, p.Trp651Ter and p.Tyr663Ter—in the last exon of COL10A1, 
a gene encoding type X collagen (Fang et al., 2013). Given that PTC recognition by an 
aberrantly long 3′ untranslated region (UTR) can activate NMD in yeast, Drosophila 
melanogaster, Caenorhabditis elegans, and plant and mammalian cells (Amrani et al., 
2004; Bühler et al., 2006; Kuroha et al., 2009; Kurosaki and Maquat., 2016), one 
plausible explanation for the unexpected SERPINB7 NMD is a 342-bp extension of its 
native 741-bp 3′ UTR resulting from c.796C>T (Figure 1a). An extended 3′ UTR that is 
devoid of EJC increases physical distance between the terminating ribosome and the 
mRNA 3′ poly(A) tail and reduces the interaction between eukaryotic release factor 3 at 
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the PTC and cytoplasmic poly(A)-binding protein 1 (PABPC1), resulting in NMD (Fang 
et al., 2013). The importance of the proximity between PABPC1 and a termination 
codon in NMD has been further supported by showing that tethering PABPC1 to a 
position sufficiently close to the 3D environment of a termination codon can inhibit 
NMD (Amrani et al., 2004). Thus, impaired translation termination at a PTC by an 
extended 3′ UTR can trigger the rapid degradation of PTC-containing mRNA (the 
so-called “faux 3′ UTR” model) (Amrani et al., 2004; Kurosaki and Maquat., 2016). 
Thus, we speculate that the extended 1083-bp 3′ UTR of the mutant SERPINB7 might 
make the mutant transcript a substrate for NMD. The involvement of the 3′ UTR in 
recognizing PTCs in genes that have a large 3′ terminal exon might represent a 
“fail-safe” RNA decay pathway to eliminate mutant transcripts that would otherwise 
escape degradation and result in C-terminally truncated proteins with potentially 
dominant-negative deleterious effects. Interestingly, EJC-independent NMD has been 
suggested to be less efficient than EJC-dependent NMD (Kurosaki and Maquat., 2016). 
This may explain why the expression level of SERPINB7 mRNA in the c.796C>T 
homozygotes was only 47% lower than that in the wild-type individuals in this study, 
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whereas EJC-dependent NMD generally reduces the PTC-containing mRNA levels to 
∼5–25% of the wild-type levels (Kervestin and Jacobson., 2012; Kuzmiak and Maquat., 
2006). 
 
Notably, we also demonstrated that truncated SERPINB7 protein from the mutant 
r.796c>u transcripts is degraded by the 26S proteasome. In yeast, mRNAs harboring a 
faux 3′ UTR stimulate Upf1-dependent proteasome-mediated degradation of the PTC 
products (Kuroha et al., 2009; Kuroha et al., 2013; Sugiyama et al., 2017). These 
findings collectively indicate that mRNA and protein stability might be regulated by the 
aberrantly long 3′ UTR of mutant transcripts in humans. The nature of SERPINB7 
mRNA decay should be further clarified in a future study, which may provide important 
insights into the mRNA/protein surveillance pathways in humans. Furthermore, 
unveiling NMD mechanisms that are specific to keratinocytes is worthwhile, because 
cell type specificity with regard to NMD has been reported (Bateman et al., 2003; 
Carter et al., 1996). Inhibition of keratinocyte-specific NMD would benefit patients 
with a broad variety of genodermatoses, including NPPK, by tissue-specifically 
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enhancing PTC readthrough. 
 
MATERIALS AND METHODS 
For extended Materials and Methods, please refer to the Supplementary Materials 
online. All in vitro assays and quantitative mRNA analyses were performed three or 
more times. 
 
Clinical study 
Eligible participants had histologically and genetically confirmed NPPK. Five 
participants were randomly assigned to application of 0.1% gentamicin ointment (MSD, 
Tokyo, Japan) on one hand and Vaseline (Pfizer, Tokyo, Japan) on the other hand 
(split-body design) and were requested to apply 0.5 g of each topical agent twice daily 
for 4 weeks. Primary endpoints were patient and investigator assessments of the 
intensity of erythema and the degree of hyperkeratosis for the gentamicin-applied hand 
and Vaseline-applied hand. For patient assessments, ratings were recorded on a 0-100 
mm VAS before and after the 4-week application. Single-blinded-investigator (TN) 
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assessments were based on a 3-point scale (improved, no change, worse). The study 
protocol was approved by the Institutional Review Board of the Hokkaido University 
Hospital (approved No. 014-0427), registered in UMIN-CTR 
(http://www.umin.ac.jp/ctr/index.htm; UMIN000018677), and conducted after obtaining 
written informed consent by all participants or their legal guardians in compliance with 
the Declaration of Helsinki Principles. 
 
Statistics 
Statistically significant differences were determined by the Student’s unpaired 
two-tailed t-test and the paired t-test for the comparison of mRNA expression levels and 
VAS scores, respectively. Data are represented as the mean ± the SEM. 
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Table 1. Summary of the NPPK patients included in this clinical study. 
Patient Age (y/o) Gender Mutation 1 Mutation 2 Left hand Right hand Previously reported?
P1 28 Male c.796C>T c.796C>T Gentamicin Vaseline Yes*
P2 29 Male c.796C>T c.796C>T Gentamicin Vaseline No
P3 6 Female c.796C>T c.455-1G>A Vaseline Gentamicin Yes*
P4 40 Female c.796C>T c.455-1G>A Vaseline Gentamicin Yes*
P5 46 Male c.796C>T c.796C>T Gentamicin Vaseline Yes*
*Mizuno et al., 2014
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FIGURE LEGENDS 
Figure 1. Gentamicin suppresses the founder nonsense mutation c.796C>T in 
SERPINB7 in vitro. (a) Schematic diagrams of wild-type and mutant SERPINB7 cDNA 
N-terminally tagged with FLAG, both driven by the CMV promoter. Luc2, encoding 
firefly luciferase (FLuc), was co-transfected as a transfection control. (b) Ribosomes 
usually stop protein translation at a PTC in the mutant SERPINB7 mRNA, producing a 
297-amino-acid (aa) truncated SERPINB7. However, readthrough drugs such as 
gentamicin promote synthesis of the 492-aa full-length SERPINB7. (c) Expression of 
full-length SERPINB7 was detected using the anti-FLAG antibody. Transient 
transfection of the mutant cDNA into AD293 cells resulted in little synthesis of 
full-length SERPINB7. However, gentamicin at a concentration of 312 µg/ml or higher 
promoted the cells to produce more full-length SERPINB7 in a dose-dependent manner. 
By contrast, ataluren did not increase the synthesis of full-length SERPINB7. G418 was 
used as a positive control. Note that gentamicin did not increase the protein levels of 
truncated SERPINB7 or FLuc. These experiments were performed more than three 
times. Representative data are shown. 
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Figure 2. Gentamicin-induced restoration of full-length SERPINB7 protein in 
NPPK keratinocytes. Western blotting analysis of NHEK cell lysates using an 
anti-N-terminal SERPINB7 antibody yielded a number of non-specific bands. siRNA 
knockdown of SERPINB7 was used to identify SERPINB7-specific bands (red arrows). 
Treating NPPK patient-derived keratinocytes with 10,000 or 15,000 µg/ml gentamicin 
for 60 hours restored the production of full-length SERPINB7. G418 was used as a 
positive control. β-actin (ACTB) was used as a loading control. The band intensities of 
SERPINB7 normalized to those of ACTB were also shown. This experiment was 
performed more than three times. Representative data are shown. 
 
Figure 3. A “proof-of-concept” compassionate use study of topical gentamicin in 
NPPK patients. In this investigator-blinded, randomized, four-week compassionate use 
study, five NPPK patients with the nonsense mutation c.796C>T were randomly 
assigned to application of 0.1% gentamicin ointment on one hand and Vaseline on the 
other. (a) The patients reported improvement of hyperkeratosis on the gentamicin side 
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in visual analog scale (VAS) scores compared with the control side. The results were 
statistically significant (P=0.0349) by the paired t-test. (b) A blinded-investigator 
assessment revealed reduced hyperkeratosis on the gentamicin-applied hand (P1 in the 
Table 1), especially on the fingers (yellow square). 
 
Figure 4. Co-translational NMD of mutant SERPINB7 transcripts harboring 
r.796c>u. (a) Quantitative real-time reverse transcriptase PCR analysis of SERPINB7 
mRNA levels in NPPK patients. The expression levels of SERPINB7 mRNA in the 
whole skin of NPPK patients who were homozygous for c.796C>T were significantly 
lower than those of the wild-type individuals (P=0.00069). (b) Cycloheximide treatment 
increased SERPINB7 mRNA levels more efficiently in immortalized NPPK 
keratinocytes with a homozygous c.796C>T mutation than in immortalized NHEKs at a 
concentration of 2.0 µM or higher. (c) siRNA knockdown of UPF1 in immortalized 
NPPK keratinocytes resulted in a significant increase in SERPINB7 mRNA levels. Note 
that expression values were normalized to 18S rRNA, and each value represents the 
mean ± the SEM for at least three independent experiments. The Student’s unpaired 
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two-tailed t-test was used for statistical analysis. 
 
Figure 5. 26S proteasome-mediated protein degradation of mutant SERPINB7 
protein. (a) Transfection of the mutant and wild-type SERPINB7 cDNA into HaCaT 
cells resulted in the production of truncated and full-length SERPINB7, respectively. 
Interestingly, the protein levels of truncated SERPINB7 were much lower than those of 
full-length SERPINB7. MG132 treatment increased the synthesis of the truncated 
protein in the mutant-transfected cells, while it did not alter the full-length SERPINB7 
levels in the wild-type-transfected cells. Firefly luciferase (FLuc) and β-actin (ACTB) 
were used as a transfection and loading control, respectively. (b) Treatment of 
immortalized NPPK keratinocytes with MG132 promoted the production of truncated 
SERPINB7 in a dose-dependent manner. Note that cycloheximide (CHX) also increased 
truncated protein synthesis. ACTB was used as a loading control. Protein loading is also 
shown by Coomassie Brilliant Blue (CBB) staining. 
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